Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support

Leukemia and Lymphoma

Volumn 49, Issue 8, 2008, Pages 1530-1536

  Nangalia, Jyoti ^a   Smith, Hannah ^a   Wimperis, Jennie Z ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

ABVD; Chemotherapy; G CSF; Hodgkin; Lymphoma; Neutropenia

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLISTER; BLOOD TOXICITY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; COST CONTROL; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFECTION; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; MONOCYTOPENIA; MONOCYTOSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; DACARBAZINE; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HODGKIN DISEASE; HUMANS; INCIDENCE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; SEPSIS; VINBLASTINE;

EID: 51349157757     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802210718     Document Type: Article

References (32)

1. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U. Hasenclever, D. et al. (2003) the German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med, 348, pp. 2386-2395.
2. Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R. Henderson, E. S. et al. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med, 327, pp. 1478-1484.
3. Duggan, D. B., Petroni, G. R., Johnson, J. L., Glick, J. H., Fisher, R. I. Connors, J. M. et al. (2003) Randomized comparison of ABVD and MOPP/ ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol, 21, pp. 607-614.
4. Johnson, P. W., Radford, J. A., Cullen, M. H., Sydes, M. R., Walewski, J. Jack, A. S. et al. (2005) United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol, 23, pp. 9208-9218.
5. Bonadonna, G., Bonfante, V., Viviani, S., Di Russo, A, Villani, F. and Valagussa, P. (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol, 22, pp. 2835-2841.
6. Carde, P., Mackintosh, F. R. and Rsenberg, S. A. (1983) A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol, 1, pp. 146-153.
7. Bezwoda, W. R., Dansey, R. and Bezwoda, M. A. (1990) Treatment of Hodgkin's disease with MOPP chemotherapy: Effect of dose and schedule modification on treatment outcome. Oncology, 47, pp. 29-36.
8. van Rijswijk, R. E., Haanen, C., Dekker, A. W., de Meijer, A. J. and Verbeek, J. (1989) Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol, 7, pp. 1776-1782.
9. Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G. Tabbara, I. et al. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med, 325, pp. 164-170.
10. Pettengell, R., Gurney, H., Radford, J. A., Deakin, D. P., James, R. Wilkinson, P. M. et al. (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood, 80, pp. 1430-1436.
11. Silvestri, F., Fanin, R., Velisig, M., Barillari, G., Virgolini, L. Zaja, F. et al. (1994) The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease. Tumor, 80, pp. 453-458.
12. Younes, A., Fayad, L., Romaguera, J., Pro, B., Goy, A. and Wang, M. (2006) Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer, 42, pp. 2976-2981.
13. Rueda, A., Sevilla, I., Guma, J., Ribelles, N., Miramon, J. De Las Nieves, M A et al. (2001) Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD. Leuk Lymphoma, 41, pp. 353-358.
14. Gustavsson, A. (1997) G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease. Acta Oncol, 36, pp. 483-488.
15. Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P. and Young, R. C. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol, 7, pp. 1630-1636.
16. Hasenclever, D. and Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. For the international prognostic factors project on advanced Hodgkin's disease. N Engl J Med, 19, pp. 1506-1514.
17. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
18. Chand, V. K., Link, B. K., Ritchie, J. M., Shannon, M. and Wooldridge, J. E. (2006) Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. Leuk Lymphoma, 47, pp. 657-663.
19. Schaefer, N. G., Taverna, C., Strobel, K., Wastl, C., Kurrer, M. and Hany, T. F. (2007) Hodgkin disease: Diagnostic value of FDG PET/CT after first-line therapy - is biopsy of FDG-avid lesions still needed?. Radiology, 244, pp. 257-262.
20. Goldie, J. H. and Coldman, A. J. (1983) Goldie qualitative model for multiple levels of drug resistance in clinical tumours. Cancer Treatment Reports, 67, pp. 923-931.
21. Bodey, G. P., Buckley, M., Sathe, Y. S. and Freireich, E. J. (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med, 64, p. 328.
22. Bow, E. J. (1998) Infection risk and cancer chemotherapy: The impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother, 41, pp. 1-5.
23. Aglietta, M., Montemurro, F., Fagioli, F., Volta, C., Botto, B. Cantonetti, M. et al. (2000) Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. Cancer, 88, pp. 454-460.
24. Riccardi, A., Gobbi, P., Danova, M., Giordano, M., Pieresca, C. Bertoloni, D. et al. (1993) MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease. Haematologica, 78, pp. 44-48.
25. Dunlop, D. J., Eatock, M. M., Paul, J., Anderson, S., Reed, N. S. Soukop, M. et al. (1998) Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol), 10, pp. 107-114.
26. Boleti, E. and Mead, G. M. (2007) ABVD for Hodgkin's lymphoma: Full-dose chemotherapy without dose reductions or growth factors. Ann Oncol, 18, pp. 376-380.
27. Evens, A. M., Cilley, J., Ortiz, T., Gounder, M., Hou, N. Rademaker, A. et al. (2007) G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: Low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol, 137, pp. 545-552.
28. Bohlius, J., Reiser, M., Schwarzer, G. and Engert, A. (2003) Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: A systematic review. Br J Haematol, 122, pp. 413-423.
29. Bohlius, J., Reiser, M., Schwarzer, G. and Engert, A. (2004) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev, 1, p. CD003189.
30. Aapro, M. S., Cameron, D. A., Pettengell, R., Bohlius, J., Crawford, J. and Ellis, M. (2006) European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer, 42, pp. 2433-2453.
31. Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O. and Balducci, L. (2006) 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol, 24, pp. 3187-3205.
32. Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E. and Ansell, S. M. (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol, 23, pp. 7614-7620.